HEPA
NASDAQHepion Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Website
News25/Ratings1
News · 26 weeks12-57%
2025-10-262026-04-19
Mix1090d
- SEC Filings6(60%)
- Insider3(30%)
- Other1(10%)
Latest news
25 items- SECSEC Form D filed by Hepion Pharmaceuticals Inc.D - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECHepion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECHepion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- INSIDERSEC Form 3 filed by new insider Stetz Gary S.3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- INSIDERSEC Form 3 filed by Hepion Pharmaceuticals Inc.3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- INSIDERSEC Form 3 filed by Hepion Pharmaceuticals Inc.3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- SECHepion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECSEC Form 10-K filed by Hepion Pharmaceuticals Inc.10-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECHepion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- PRHepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular CarcinomaNext-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion's strategic shift to advancing clinically proven liquid biopsy tests under new leadership MORRISTOWN, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a precision diagnostics company, today announced that it has in-licensed from Cirna Diagnostics LLC, a novel biomarker assay that detects mutant circulating tumor RNA (ctRNA) to facilitate early diagnosis of hepatocellular carcinoma (HCC) in high-risk patients (cirrhosis). Most cases of liver cancer (75-90%) are HCC, and HCC is the sixth most common cancer w
- SECSEC Form 8-K filed by Hepion Pharmaceuticals Inc.8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECSEC Form 10-Q filed by Hepion Pharmaceuticals Inc.10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Hepion Pharmaceuticals Inc.SCHEDULE 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
- SECSEC Form 10-Q filed by Hepion Pharmaceuticals Inc.10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECSEC Form 25-NSE filed by Hepion Pharmaceuticals Inc.25-NSE - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
- SECSEC Form 8-K filed by Hepion Pharmaceuticals Inc.8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- PRHepion Pharmaceuticals Successfully Completes Application to the OTCQBMORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that it has successfully completed the process of transitioning to the OTCQB Venture Market. The Company's common stock begins trading on the OTCQB Venture Market today, June 25, 2025 with the trading symbol, HEPA. About Hepion Pharmaceuticals Hepion is a clinical stage biopharmaceutical company that is developing and commercializing diagnost
- PRHepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive OfficerMORRISTOWN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTC:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that Dr. Kaouthar Lbiati has been named as interim Chief Executive Officer, effective June 16, 2025. Dr. Lbiati is replacing John Brancaccio, who is retiring for personal reasons. Dr. Lbiati's appointment signals a new chapter for Hepion—one focused on strategic renewal, value creation, and diagnostic innovation in areas of significant unmet clin
- SECHepion Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECHepion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECSEC Form 8-K filed by Hepion Pharmaceuticals Inc.8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECSEC Form 10-Q filed by Hepion Pharmaceuticals Inc.10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECSEC Form SCHEDULE 13G filed by Hepion Pharmaceuticals Inc.SCHEDULE 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
- SECSEC Form NT 10-Q filed by Hepion Pharmaceuticals Inc.NT 10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECHepion Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)